Codiak BioSciences Announces Program Reprioritization and Corporate Restructuring

Provided By Globe Newswire

Last update: Aug 30, 2022

– Enrollment continues in Phase 1 clinical trial of IV-administered exoASO™-STAT6 in patients with advanced hepatocellular carcinoma –

– Prioritizing vaccine program funded by CEPI and advancement of engEx-AAV™ for gene delivery –